Race's first important asset is a chemotherapy drug called Bisantrene which was the subject of more than 40 phase II clinical studies before it was lost in a series of pharmaceutical mergers during the 1990s. Race Oncology has rediscovered Bisantrene and we plan to put this valuable drug back in the hands of clinicians to treat Leukaemia.
We own recent patent filings on Bisantrene and have secured Orphan Drug Designation in the US. We now aim to bring this valuable drug to market.
Race Oncology CEO Peter Molloy and Chair Dr Bill Garner.
Race Oncology Non-Executive Director Dr. John Cullity speaks with Proactive Investors about the
New Race non-executive director Dr John Cullity has used his first interview to highlight the
Race Oncology has announced it has executed a global distribution agreement with UK-based,
Race Oncology is pleased to announce the appointment of US-based Dr John Cullity as a
In a major development for the Australian biotech sector, ASX-listed oncology drug developer,
Race Oncology’s second Bisantrene patent has received “Notice of Allowance” in the US.